These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 6376558)

  • 41. Multicenter trial of fluocinonide in an emollient cream base.
    Fisher M; Kelly AP
    Int J Dermatol; 1979 Oct; 18(8):660-4. PubMed ID: 389843
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of refractory psoriasis with fluocinonide gel.
    Willoughby CB; Cook WR
    Cutis; 1977 Jul; 20(1):144-5. PubMed ID: 884957
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antimelanoma immunity in vitiligo and melanoma patients.
    Juranic ZD; Stanojevic-Bakic N; Zizak Z; Babovic N; Radovic-Kovacevic V; Stanojkovic T; Dzodic R
    Neoplasma; 2003; 50(4):305-9. PubMed ID: 12937846
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo.
    Uchi H; Stan R; Turk MJ; Engelhorn ME; Rizzuto GA; Goldberg SM; Wolchok JD; Houghton AN
    Adv Immunol; 2006; 90():215-41. PubMed ID: 16730265
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vitiligo.
    Dunn JF
    Am Fam Physician; 1986 May; 33(5):137-43. PubMed ID: 3706094
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ocular abnormalities associated with cutaneous melanoma and vitiligolike leukoderma.
    Chang MA; Fournier G; Koh HK; Sober AJ; Nakagawa H; Fitzpatrick TB; Albert DM
    Graefes Arch Clin Exp Ophthalmol; 1986; 224(6):529-35. PubMed ID: 3792849
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of non-inflammatory dermatoses. A double-blind comparison of 1% hydrocortisone plus 10% urea and 0.05% fluocinonide.
    Khan SA
    Practitioner; 1978 Aug; 221(1322):265-7. PubMed ID: 364458
    [No Abstract]   [Full Text] [Related]  

  • 48. Immunological associations of the halo naevus with cutaneous malignant melanoma.
    Copeman PW; Lewis MG; Phillips TM; Elliott PG
    Br J Dermatol; 1973 Feb; 88(2):127-37. PubMed ID: 4574770
    [No Abstract]   [Full Text] [Related]  

  • 49. [Autoantibodies in vitiligo. Clinical significance].
    Morgan M; Castells A; Ramírez A
    Med Cutan Ibero Lat Am; 1986; 14(2):139-42. PubMed ID: 3528710
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells.
    Cui J; Bystryn JC
    Arch Dermatol; 1995 Mar; 131(3):314-8. PubMed ID: 7887661
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fluorescent antibody studies in malignant melanoma.
    Whitehead RH
    Br J Cancer; 1973 Dec; 28(6):525-9. PubMed ID: 4205845
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vitiligo and malignant melanoma.
    Fodor J; Bodrogi I
    Neoplasma; 1975; 22(4):445-8. PubMed ID: 1196428
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Double-blind comparison of a dithranol and steroid mixture with a conventional dithranol regimen for chronic psoriasis.
    Grattan CE; Christopher AP; Robinson M; Cowan MA
    Br J Dermatol; 1988 Nov; 119(5):623-6. PubMed ID: 3061441
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Treatment of superficially infected dermatoses with topsym polyvalent ointment (CG3225) (author's transl)].
    Zala L
    Ther Umsch; 1977 Oct; 34(10):748-50. PubMed ID: 72423
    [No Abstract]   [Full Text] [Related]  

  • 55. Significance of malignant melanoma antigen (melanoma specific protein) in the urine.
    Copeman PW; Cooke KB
    J R Soc Med; 1979 Feb; 72(2):95-9. PubMed ID: 552487
    [No Abstract]   [Full Text] [Related]  

  • 56. Immunotherapy-induced leukoderma from treatment of melanoma with IL-2: a case report and a review of the literature.
    Gathings R; Lewallen R; Yosipovitch G
    Acta Derm Venereol; 2015 Feb; 95(2):197-200. PubMed ID: 24820241
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy.
    Roenigk HH; Martin JS; Eichorn P; Gilliam JN
    Cutis; 1980 Mar; 25(3):281-5. PubMed ID: 6987043
    [No Abstract]   [Full Text] [Related]  

  • 58. [Vitiligo].
    Njoo MD; Westerhof W
    Ned Tijdschr Geneeskd; 1997 Apr; 141(16):759-64. PubMed ID: 9213796
    [TBL] [Abstract][Full Text] [Related]  

  • 59. On the etiology of vitiligo and gray hair.
    Lerner AB
    Am J Med; 1971 Aug; 51(2):141-7. PubMed ID: 5095523
    [No Abstract]   [Full Text] [Related]  

  • 60. Fluocinonide vs halcinonide in atopic dermatitis. A paired comparison of two potent topical corticosteroids.
    Silverman A
    Cutis; 1979 Mar; 23(3):375-8. PubMed ID: 369775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.